Literature DB >> 15723164

Androgens, andropause and neurodegeneration: exploring the link between steroidogenesis, androgens and Alzheimer's disease.

K A Bates1, A R Harvey, M Carruthers, R N Martins.   

Abstract

The relationship between menopause and cognitive decline has been the subject of intense research since a number of studies have shown that hormone replacement therapy could reduce the risk of developing Alzheimer's disease in women. In contrast, research into andropause has only recently begun. Furthermore, evidence now suggests that steroidogenesis is not restricted to the gonads and adrenals, and that the brain is capable of producing its own steroid hormones, including testosterone and estrogen. Sex hormones have been demonstrated to be of critical importance in the embryonic development of the central nervous system (CNS); however, we are only just beginning to understand the role that these hormones may play in the normal functioning and repair of the adult mammalian CNS. This review will summarize current research into the role of androgens and andropause on cognition and the possible mechanisms of action of androgens, with particular reference to Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723164     DOI: 10.1007/s00018-004-4383-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  20 in total

1.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.

Authors:  Dolly A Parasrampuria; Thomas Marbury; Nobujo Matsushima; Shuquan Chen; Prachi K Wickremasingha; Ling He; Victor Dishy; Karen S Brown
Journal:  Thromb Haemost       Date:  2015-01-08       Impact factor: 5.249

3.  A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

Authors:  Stephan Glund; Viktoria Moschetti; Stephen Norris; Joachim Stangier; Michael Schmohl; Joanne van Ryn; Benjamin Lang; Steven Ramael; Paul Reilly
Journal:  Thromb Haemost       Date:  2015-03-19       Impact factor: 5.249

4.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control.

Authors:  Allan C Skanes; Jeff S Healey; John A Cairns; Paul Dorian; Anne M Gillis; M Sean McMurtry; L Brent Mitchell; Atul Verma; Stanley Nattel
Journal:  Can J Cardiol       Date:  2012 Mar-Apr       Impact factor: 5.223

5.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

6.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321

7.  Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.

Authors:  Elaine M Hylek; Claes Held; John H Alexander; Renato D Lopes; Raffaele De Caterina; Daniel M Wojdyla; Kurt Huber; Petr Jansky; Philippe Gabriel Steg; Michael Hanna; Laine Thomas; Lars Wallentin; Christopher B Granger
Journal:  J Am Coll Cardiol       Date:  2014-03-19       Impact factor: 24.094

8.  A specific antidote for dabigatran: functional and structural characterization.

Authors:  Felix Schiele; Joanne van Ryn; Keith Canada; Corey Newsome; Eliud Sepulveda; John Park; Herbert Nar; Tobias Litzenburger
Journal:  Blood       Date:  2013-03-08       Impact factor: 22.113

9.  Rates of hemorrhage during warfarin therapy for atrial fibrillation.

Authors:  Tara Gomes; Muhammad M Mamdani; Anne M Holbrook; J Michael Paterson; Chelsea Hellings; David N Juurlink
Journal:  CMAJ       Date:  2012-11-26       Impact factor: 8.262

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

View more
  8 in total

1.  Changes in cytochrome P450 side chain cleavage expression in the rat hippocampus after kainate injury.

Authors:  Wan-Jie Chia; Andrew M Jenner; Akhlaq A Farooqui; Wei-Yi Ong
Journal:  Exp Brain Res       Date:  2007-11-27       Impact factor: 1.972

2.  Identification of a regulatory loop for the synthesis of neurosteroids: a steroidogenic acute regulatory protein-dependent mechanism involving hypothalamic-pituitary-gonadal axis receptors.

Authors:  Sivan Vadakkadath Meethal; Tianbing Liu; Hsien W Chan; Erika Ginsburg; Andrea C Wilson; Danielle N Gray; Richard L Bowen; Barbara K Vonderhaar; Craig S Atwood
Journal:  J Neurochem       Date:  2009-05-29       Impact factor: 5.372

Review 3.  Neurodegenerative mutants in Drosophila: a means to identify genes and mechanisms involved in human diseases?

Authors:  Doris Kretzschmar
Journal:  Invert Neurosci       Date:  2005-10-24

4.  Progressive and unconventional pharmacotherapeutic approaches to Alzheimer's disease therapy.

Authors:  Stuart Maudsley; Wayne Chadwick
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

Review 5.  The gonadotropin connection in Alzheimer's disease.

Authors:  Sivan Vadakkadath Meethal; Mark A Smith; Richard L Bowen; Craig S Atwood
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

6.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

7.  MR-10 Enhances Men's Health by Improving Endogenous Male Sex Hormone Generation.

Authors:  Yoo-Hun Noh
Journal:  J Med Food       Date:  2018-09-04       Impact factor: 2.786

8.  Time for international action on treating testosterone deficiency syndrome.

Authors:  Malcolm Carruthers
Journal:  Aging Male       Date:  2009-03       Impact factor: 5.892

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.